42m
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab - a CD38-directed ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab - a CD38-directed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results